|Other names||BHV-3000, BMS-927711|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||534.568 g·mol−1|
|3D model (JSmol)|
Rimegepant (BHV-3000; formerly BMS-927711) is an investigational drug candidate for the treatment of migraine. Originally discovered at Bristol-Myers Squibb, it is currently under development by Biohaven Pharmaceuticals.
Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|